Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome, known as PAPA syndrome, is a rare genetic condition that causes recurring joint inflammation, painful skin ulcers, and severe acne, often running in families and beginning in early childhood with symptoms that can significantly affect a person’s quality of life.

Understanding Treatment Goals and Approaches for PAPA Syndrome

When someone is diagnosed with PAPA syndrome, the main aim of treatment is to control the often painful and disabling symptoms that affect both the joints and the skin. Because this condition is so rare—only 34 patients have been documented worldwide from five families—developing a clear treatment plan can be challenging for both doctors and patients. The primary goals are to reduce inflammation, prevent permanent damage to the joints, heal the painful skin ulcers, manage the severe acne, and ultimately improve the person’s ability to carry out daily activities without constant pain and discomfort.^[1][2]

Treatment strategies depend heavily on which symptoms are most prominent at any given time and how severe they are. For example, a child might first experience episodes of joint swelling and pain, while skin problems like pyoderma gangrenosum and cystic acne may not appear until adolescence. This means that doctors need to adjust their approach as the patient grows and as different symptoms emerge or become more severe. The stage of the disease and the individual characteristics of each patient—such as their age, overall health, and which symptoms are causing the most trouble—all play a role in deciding the best course of action.^[2]

There are established treatments that have been used by medical experts based on experience with similar inflammatory conditions, even though large clinical studies specifically for PAPA syndrome are difficult to conduct due to its rarity. At the same time, researchers are exploring new therapies through clinical trials, testing innovative drugs that target specific parts of the immune system that appear to go wrong in this condition. These newer treatments offer hope for better control of symptoms and fewer side effects compared to older medications.^[3]

Standard Treatment Approaches for PAPA Syndrome

The traditional cornerstone of treatment for PAPA syndrome has been medications called glucocorticoids, which are powerful anti-inflammatory drugs. Glucocorticoids, commonly known as steroids, work by dampening down the immune system’s overactive response that causes the painful joint swelling and skin ulcers. Doctors have reported that both the arthritis and the skin lesions in PAPA syndrome patients sometimes respond well to glucocorticoid treatment. These medications can be given as tablets taken by mouth, or in severe cases, injected directly into an affected joint or given intravenously into a vein for faster action.^[3]

However, glucocorticoids come with a range of potential side effects, especially when used for long periods or at high doses. These can include weight gain, increased risk of infections because the immune system is suppressed, weakening of the bones (called osteoporosis), high blood sugar levels, mood changes, and growth problems in children. Because of these concerns, doctors try to use the lowest dose that still controls the symptoms, and they look for other medications that can be added or used instead to reduce the need for steroids.^[2]

For the severe cystic acne that often develops during adolescence in people with PAPA syndrome, dermatologists may recommend standard acne treatments. One common option is oral tetracycline antibiotics, such as doxycycline or minocycline. These medications work not only by fighting bacteria that can worsen acne but also by reducing inflammation in the skin. Another powerful medication used for severe acne is isotretinoin, which is derived from vitamin A. Isotretinoin works by shrinking the oil glands in the skin, reducing oil production, and helping to prevent the blocked pores that lead to cystic acne. This medication requires careful monitoring because it can cause serious birth defects if taken during pregnancy, and it can also affect the liver and cholesterol levels in the blood.^[4]

Traditional immunosuppressant medications, which are drugs used to treat other autoimmune and inflammatory conditions like rheumatoid arthritis and inflammatory bowel disease, may also be tried in PAPA syndrome. These include medications such as methotrexate, azathioprine, or cyclosporine. The idea is to calm down the immune system more broadly to reduce the inflammation affecting both the joints and the skin. However, the evidence for how well these work specifically in PAPA syndrome is limited because so few people have the condition.^[4]

The duration of treatment varies greatly from person to person. Some individuals may need continuous medication to keep symptoms under control, while others might experience periods when the disease is less active and medications can be reduced or temporarily stopped. Because PAPA syndrome tends to improve as people get older—with joint symptoms often lessening while skin problems may continue—the treatment plan needs to be regularly reviewed and adjusted. Long-term follow-up with doctors who specialize in rheumatology (for joint problems) and dermatology (for skin problems) is essential to monitor the disease and manage any side effects of treatment.^[2]

Emerging Treatments Being Tested in Clinical Trials

One of the most promising developments in treating PAPA syndrome has been the use of medications called biological response modifiers or biologics. These are sophisticated drugs designed to target very specific parts of the immune system that appear to be overactive in inflammatory conditions. Unlike traditional immunosuppressants that broadly dampen the immune system, biologics are more precise, aiming at particular molecules or pathways involved in causing inflammation. This targeted approach can potentially offer better symptom control with fewer side effects.^[4]

One group of biologics that has shown success in PAPA syndrome targets a molecule called tumor necrosis factor, often abbreviated as TNF. TNF is a protein produced by immune cells that plays a central role in causing inflammation. When there is too much TNF, it can lead to the kind of damaging inflammation seen in PAPA syndrome. Medications that block TNF include etanercept, infliximab, and adalimumab. These drugs work by binding to TNF and preventing it from triggering inflammatory responses in the body.^[4][11]

There have been case reports describing patients with PAPA syndrome whose disease underwent rapid and sustained improvement after starting treatment with etanercept, one of the TNF inhibitor drugs. The arthritis became much less painful and the frequency of joint flares decreased significantly. The pyoderma gangrenosum ulcers also began to heal, and the severe acne improved. These encouraging results suggest that blocking TNF can be an effective strategy for controlling the multiple symptoms of PAPA syndrome, although more patients need to be studied to confirm these benefits.^[3]

Another extremely promising treatment approach involves targeting a different inflammatory molecule called interleukin-1, or IL-1. IL-1 is another key protein involved in inflammation, and scientists have discovered that it appears to be particularly important in the disease process of PAPA syndrome. A medication called anakinra works by blocking the action of IL-1. Anakinra is a recombinant (laboratory-made) version of a protein that naturally occurs in the human body called IL-1 receptor antagonist, which normally helps control inflammation by preventing IL-1 from sending its inflammatory signals.^[7]

Case reports have described patients with PAPA syndrome who were treated with anakinra and experienced remarkable improvements. One report detailed how a patient with severe, non-healing pyoderma gangrenosum ulcers that had not responded to other treatments showed significant healing after starting anakinra. The patient also experienced relief from joint pain and improvement in overall quality of life. The medication appeared to be effective in treating disease flares when symptoms suddenly worsened. Anakinra is given as a daily injection under the skin, which some patients find inconvenient, but the benefits in controlling symptoms have been described as substantial.^[7][3]

These biologics—both the TNF inhibitors and the IL-1 blockers—represent what could be considered Phase IV treatments in the sense that they are already approved medications for other conditions (such as rheumatoid arthritis), and doctors are using them “off-label” for PAPA syndrome based on clinical judgment and case reports. Off-label use means prescribing a medication for a condition that it was not originally approved to treat, which is common practice when dealing with rare diseases where conducting large clinical trials is not feasible. The mechanism of action is well understood: these drugs interrupt specific inflammatory pathways that are overactive in PAPA syndrome, thereby reducing the inflammation that damages joints and skin.^[4]

Regarding where such treatments might be available, patients with PAPA syndrome are typically managed at specialized centers with expertise in rare autoinflammatory diseases. These centers can be found in various countries including the United States, several European nations, and other regions with advanced healthcare systems. Given the rarity of the condition, patients may need to travel to academic medical centers or hospitals with specific expertise in genetics, rheumatology, and dermatology. Access to these newer biologic treatments depends on factors including healthcare system coverage, medication availability in different countries, and whether the patient meets eligibility criteria for compassionate use or clinical observation programs when formal trials are not available.^[1][3]

Understanding How Symptoms and Treatment Needs Change Over Time

One important aspect of PAPA syndrome that affects treatment decisions is that the disease does not stay the same throughout a person’s life. The condition typically begins with joint problems in early childhood, often between the ages of 1 and 10 years. These early episodes of arthritis can be quite severe and may be triggered by minor injuries or occur spontaneously without any clear cause. The affected joint becomes swollen, red, painful, and warm to the touch. The inflammation can look so much like a bacterial infection that doctors initially may suspect septic arthritis, which is joint inflammation caused by bacteria. However, when fluid is taken from the joint and tested, no bacteria are found, which is why it is called “sterile” arthritis.^[2]

As children with PAPA syndrome grow older, an interesting pattern often emerges: the joint symptoms may become less frequent and less severe, particularly as they enter their teenage years. However, this is also when the skin problems typically become more prominent. Pyoderma gangrenosum, which consists of large, painful ulcers with raised, undermined edges, usually appears during adolescence and beyond. These ulcers most commonly affect the legs but can occur anywhere on the body. A characteristic feature is something called pathergy, which means that skin ulcers can be triggered by minor injuries, surgical procedures, or even something as simple as an injection or intravenous line placement.^[2][4]

The severe cystic acne also typically develops during the teenage years and can persist well into adulthood. This is not ordinary acne—it involves deep, painful lumps under the skin that can lead to significant scarring if not properly treated. The combination of pyoderma gangrenosum ulcers and severe acne can be emotionally distressing for young people and can significantly impact their self-esteem and social interactions during already challenging developmental years.^[2]

This changing pattern of symptoms means that treatment priorities shift over time. In early childhood, the focus is primarily on controlling the joint inflammation and preventing permanent joint damage, which can result from repeated inflammatory attacks. As the patient enters adolescence, treatment attention shifts more toward managing the skin manifestations. Throughout all stages, the goal is to maintain the best possible quality of life while minimizing medication side effects.^[2]

Most common treatment methods

• Anti-inflammatory medications
  • Glucocorticoids (steroids) are sometimes reported to be responsive for both arthritis and skin lesions, used to dampen immune system overactivity
  • These can be administered orally, through injection into affected joints, or intravenously depending on severity
  • Long-term use requires monitoring for side effects including weight gain, infection risk, bone weakening, and growth problems in children
• Acne treatments
  • Oral tetracycline antibiotics (such as doxycycline or minocycline) may be required for severe cystic acne
  • Isotretinoin, a vitamin A derivative, may be needed for severe nodulocystic acne that does not respond to other treatments
  • Isotretinoin requires careful monitoring due to potential effects on liver function, cholesterol levels, and serious risk of birth defects
• Biologic therapies (TNF inhibitors)
  • Etanercept has been reported to produce rapid and sustained clinical remission in case reports
  • Infliximab and adalimumab have shown good response in resistant arthritis and pyoderma gangrenosum
  • These medications work by blocking tumor necrosis factor, a key protein that drives inflammation
• Interleukin-1 blockade
  • Anakinra (recombinant human IL-1 receptor antagonist) appeared to be effective therapy to treat disease flares
  • This medication has been described in reports as showing rapid improvement in pyoderma gangrenosum ulcers
  • Given as daily subcutaneous injection, it works by blocking the inflammatory effects of interleukin-1
• Traditional immunosuppressants
  • Other traditional immunosuppressant treatments for arthritis or pyoderma gangrenosum may be used
  • These may include medications like methotrexate, azathioprine, or cyclosporine to broadly suppress immune activity

The Genetic Basis and Why Treatment Cannot Prevent the Disease

Understanding the genetic cause of PAPA syndrome helps explain why current treatments focus on managing symptoms rather than preventing or curing the disease. PAPA syndrome is caused by mutations in a gene called PSTPIP1 (which stands for proline-serine-threonine phosphatase interacting protein 1). This gene was previously known by another name, CD2BP1 (CD2 binding protein 1). The gene provides instructions for making a protein that plays an important role in regulating how the immune system responds to threats and controls inflammation.^[2][3]

When the PSTPIP1 gene has a mutation, the protein it produces doesn’t work properly. Scientists have found that only two specific mutations account for the known cases of PAPA syndrome. These mutations cause the protein to interact abnormally with another protein called pyrin (or marenostrin), which is encoded by the MEFV gene. Interestingly, mutations in the MEFV gene cause a different condition called Familial Mediterranean Fever. The PSTPIP1 mutations found in PAPA syndrome cause the PSTPIP1 protein to bind too strongly to pyrin, and this increased binding appears to trigger excessive inflammatory responses.^[3]

PAPA syndrome is inherited in an autosomal dominant pattern. This means that a person only needs one copy of the mutated gene (from one parent) to develop the condition. If one parent has PAPA syndrome, there is a 50 percent chance that each of their children will inherit the mutation and potentially develop the disease. However, the syndrome shows what geneticists call “variable expressivity” and “incomplete penetrance.” Variable expressivity means that different people with the same mutation may have different symptoms or different severity of symptoms. Some family members might have severe joint problems and skin ulcers, while others might have only mild acne or only joint issues. Incomplete penetrance means that some people who carry the mutation might have very mild symptoms or occasionally no symptoms at all, though they can still pass the gene to their children.^[2][3]

Because PAPA syndrome is a genetic condition present from birth, it cannot be prevented with current medical knowledge. The disease is not caused by anything the parents did during pregnancy or by environmental factors—it is simply the result of inheriting or developing a mutation in the PSTPIP1 gene. This is why treatment focuses entirely on managing the symptoms: reducing inflammation when joints flare up, treating the skin ulcers and acne, preventing permanent joint damage, and helping people maintain the best possible quality of life despite their condition.^[2]